A 40-year-old male patient—referred to as Mr. Cheng—was rushed to the hospital after experiencing acute abdominal pain following frequent business dinners. Laboratory testing revealed a critically elevated serum triglyceride level of 58.75 mmol/L—more than 30 times the upper limit of normal (<1.7 mmol/L). His clinical picture was further complicated by long-standing heavy alcohol use and obesity, placing him at imminent risk for life-threatening complications such as acute pancreatitis or hyperviscosity syndrome. A multidisciplinary team initiated urgent lipid-lowering therapy and supportive care, successfully stabilizing his condition. This case has drawn heightened attention among working professionals, prompting widespread online queries—including whether the novel cholesterol absorption inhibitor hyzetimibe (marketed in China as Saishimei Hyzetimibe Tablets) can be used safely and effectively in individuals with diet- and alcohol-related hyperlipidemia.
Hyzetimibe is a second-generation, domestically developed cholesterol absorption inhibitor approved in China for the treatment of primary hypercholesterolemia—including both heterozygous familial and non-familial forms. It acts selectively in the small intestine to inhibit the Niemann-Pick C1-like 1 (NPC1L1) transporter, thereby reducing dietary and biliary cholesterol uptake and decreasing cholesterol delivery to the liver. This mechanism leads to upregulation of hepatic LDL receptors and enhanced clearance of circulating low-density lipoprotein cholesterol (LDL-C).
Clinical trial data support its efficacy: monotherapy with hyzetimibe 10 mg daily reduces LDL-C by approximately 15% compared with placebo. When added to background statin therapy, hyzetimibe 20 mg daily provides an *additional* LDL-C reduction of ~16% beyond that achieved with statins alone. The combination yields cumulative LDL-C reductions exceeding 50%—a threshold associated not only with plaque stabilization but also with measurable regression of coronary atherosclerosis and significantly reduced cardiovascular event risk. Importantly, long-term combination therapy does not increase the incidence of adverse events relative to statin monotherapy, including transaminase elevations or myalgia.
For professionals with demanding social schedules—characterized by frequent alcohol consumption and high-fat meals—the “statin + hyzetimibe” regimen represents a guideline-endorsed therapeutic advancement. As outlined in the Chinese Guidelines for the Management of Dyslipidemia (2023 Edition), this dual-pathway approach is particularly appropriate when statin monotherapy fails to achieve LDL-C targets, when patients exhibit statin intolerance, or when hepatic metabolic burden is already elevated due to chronic alcohol exposure or nonalcoholic fatty liver disease.
A key pharmacokinetic advantage of hyzetimibe is its balanced dual-elimination pathway—undergoing both hepatic metabolism and renal excretion—with an overall systemic clearance rate of up to 93%. Notably, it is one of the few cholesterol absorption inhibitors explicitly indicated for use in patients with *moderate hepatic impairment* without dose adjustment—a critical consideration for individuals whose liver function may already be compromised by lifestyle-related factors.
Effective lipid management demands integration of pharmacologic intervention and sustained lifestyle modification:
Dietary strategies for high-risk occupational groups:
• Prioritize steamed, poached, or blanched dishes during business meals;
• Choose lean white meats—such as skinless poultry or fatty fish rich in omega-3 fatty acids;
• Limit alcohol intake strictly; avoid mixing beverages or consuming on an empty stomach;
• Follow heavy meals with a recovery day emphasizing vegetables, fruits, whole grains, and hydration.
Pharmacologic stewardship:
• Monitor fasting lipid profiles (total cholesterol, LDL-C, HDL-C, triglycerides) and liver enzymes (ALT, AST) at baseline and regularly during treatment;
• Adhere strictly to prescribed regimens—never self-adjust doses or discontinue therapy without clinical evaluation;
• Recognize that even after lifestyle improvements or transient normalization of lipid values, ongoing pharmacologic therapy remains essential for secondary prevention in established hypercholesterolemia.
Long-term cardiovascular health planning:
• Engage in ≥150 minutes per week of moderate-intensity aerobic activity (e.g., brisk walking, cycling);
• Maintain BMI within the healthy range (<24 kg/m²);
• Undergo annual comprehensive cardiovascular risk assessment—including blood pressure, glycemic status, carotid intima-media thickness, and coronary artery calcium scoring where appropriate.
In summary, hyzetimibe—particularly in combination with statins—is a clinically validated, guideline-supported option for patients with lifestyle-acquired hypercholesterolemia. However, its use must be individualized: clinicians weigh baseline LDL-C levels, hepatic and renal function, concomitant medications, and absolute cardiovascular risk before initiating therapy. For professionals navigating persistent dietary and alcohol-related challenges, sustainable behavior change—paired with evidence-based pharmacotherapy—remains the cornerstone of preventing atherosclerotic cardiovascular disease.